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Dennis DixonThe article to which this commentary refers can be found here: http://www.trialsjournal.com/content/15/1/68The well-written manuscript has lead me to reflect on
the present state of the art of designing early trials, not
necessarily limited to trials of investigational vaccines.
Standard trial designs are inadequate for this trial, as the
authors demonstrate by their careful literature search
and review. In fact, more and more research plans seem
to need one or another departure from standard designs.
Maybe the traditional paradigm of choosing a design
that: (a) has been ‘credentialed’ by publication in a peer-
reviewed methodology journal; and (b) is as close as pos-
sible to matching the actual research objectives of the
investigators, even if not a precise match, is obsolete.
Richert et al. illustrate a new paradigm, which may
well be their real contribution. They summarize what is
already known about the various effects of the candidate
vaccine strategies. They carefully state what new know-
ledge they seek. They describe the proposed trial with all
its specifications and assumptions, including those nee-
ded for them to study the design’s statistical properties.
They describe the simulation study they performed, in
enough detail that others could reproduce it, and tabu-
late the results. In fact, not only could others undertake
to reproduce their results, it is clear how to proceed to
study other specifications and assumptions.
What are the implications of following the new pa-
radigm rather than the old one? Two come to mind
readily. With regard to peer review of the clinical trial,
evaluation of the design under the old paradigm would
very often end with an observation that the proposed
study employs a well-established plan as published by
Gehan [1] or Simon [2] or Thall and Cheng [3] (and so
on). Under the new paradigm, that would almost neverCorrespondence: dd23a@verizon.net
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scientist would be needed. I note that, in the U.S., at least,
Institutional Review Boards (IRBs) (ethics review) have to
address the validity of the science of each project, but many
IRBs lack statistics expertise. The situation may be better in
the context of reviewing funding applications, although
peer reviewers rarely see full protocols in final form.
Another implication is a dramatic decline in articles
on experimental design of trials in the statistical and trial
methodology literature. Each new trial would follow the
paradigm, but the particulars would be essentially unique.
This is a less worrisome consequence, since professional
statisticians can presumably find other ways to qualify for
career advancement.Acknowledgments
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